GSK's Bepirovirsen Accepted for EMA Review
Ticker: GSK · Form: 6-K · Filed: Mar 27, 2026 · CIK: 0001131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GSK) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, EMA, drug-development
TL;DR
GSK's Bepirovirsen submission gets EMA review nod, big step for new drug.
AI Summary
GSK plc announced on March 27, 2026, that their submission for Bepirovirsen has been accepted for review by the European Medicines Agency (EMA). This acceptance marks a significant step in the regulatory process for the company's potential new treatment.
Why It Matters
The EMA's acceptance for review is a crucial milestone, indicating that Bepirovirsen is progressing towards potential market approval as a new treatment option.
Risk Assessment
Risk Level: low — This filing is an update on a regulatory submission and does not involve financial transactions or significant operational changes.
Key Players & Entities
- GSK plc (company) — Filer of the report
- Bepirovirsen (drug_name) — The subject of the EMA review
- European Medicines Agency (EMA) (company) — Regulatory body reviewing the submission
- March 27, 2026 (date) — Date of the filing and report period
FAQ
What is Bepirovirsen?
Bepirovirsen is a drug developed by GSK plc that has been submitted for review by the European Medicines Agency (EMA).
What is the significance of the EMA's acceptance for review?
The EMA's acceptance for review means that the regulatory agency will now formally assess the data submitted for Bepirovirsen, moving it closer to potential approval.
When was this filing submitted?
This filing was submitted on March 27, 2026.
What is the CIK number for GSK plc?
The CIK number for GSK plc is 0001131399.
What type of form is this SEC filing?
This is a Form 6-K, which is a report of a foreign issuer.
Filing Stats: 1,240 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2026-03-27 07:37:58
Filing Documents
- a2767y.htm (6-K) — 41KB
- 0001654954-26-002848.txt ( ) — 42KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: March 27, 2026         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc